Soka, Japan

Akira Someya

This inventor holds 1 USPTO granted patent. Top assignee: Banyu Pharmaceutical Co. Ltd. Active years: 1991.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Akira Someya. Retrieved from https://idiyas.com/inventor/akira-someya-10f24k6g

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Akira Someya: Innovator in Antiviral Agents

Introduction

Akira Someya is a notable inventor based in Soka, Japan. He has made significant contributions to the field of antiviral agents, particularly in the development of an anti-influenza agent. His work is crucial in the ongoing battle against viral infections.

Latest Patents

Akira Someya holds 1 patent for an antiviral agent that comprises a p-guanidinobenzoic acid derivative. This innovative compound serves as an active ingredient in combating influenza, showcasing his dedication to improving public health.

Career Highlights

Someya is associated with Banyu Pharmaceutical Co. Ltd., where he has been instrumental in research and development. His expertise in antiviral agents has positioned him as a key player in the pharmaceutical industry.

Collaborations

Someya has worked alongside talented colleagues, including Akira Okuyama and Takashi Murai. Their collaborative efforts have contributed to advancements in antiviral research.

Conclusion

Akira Someya's work in developing antiviral agents highlights his commitment to innovation in healthcare. His contributions are vital in the fight against influenza and other viral diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…